Business Context and Reporting Period
Company: Clene Inc. (CLNN)
Filing Type: Form 8-K (Current Report)
Date of Report: September 30, 2024
Principal Business: Biopharmaceutical company focused on the clinical development of its lead drug candidate, CNM-Au8.
Key Financial Metrics and Transaction Details
This filing details a capital raise through a registered offering and concurrent private placements. The filing does not provide historical revenue, profit, or cash flow metrics for the period.
- Registered Offering (Accredited Investor):
- 725,000 shares of Common Stock at $4.713/share.
- 17,626 Pre-Funded Warrants at ~$4.712/share.
- 742,626 Restricted Warrants at $0.125/warrant (Exercise Price: $4.82).
- Expected Gross Proceeds: Approximately $3.5 million.
- Private Placements (Current Investors):
- 257,111 Restricted Shares at $4.713/share.
- 424,358 Restricted Pre-Funded Warrants.
- 681,469 Restricted Warrants.
- Private Placements (Affiliate Investors):
- 122,819 Restricted Shares at $4.75/share.
- 122,819 Restricted Warrants.
- Total Expected Gross Proceeds (Private Placements): Approximately $3.8 million.
- Placement Agent Fees: 6.00% of gross proceeds from the registered offering plus reimbursement of legal expenses up to $75,000.
Material Changes and Use of Proceeds
The primary material change is the entry into definitive agreements to raise capital. The filing does not report changes to prior period financial performance.
- Use of Proceeds: Net proceeds will fund general corporate purposes, specifically:
- Clinical development of lead drug candidate CNM-Au8 (ongoing and planned trials).
- Potential future commercialization efforts.
- Regulatory activities and filings.
- Early-stage research and development.
- Closing Date: Expected on or about October 1, 2024.
Guidance, Risks, and Contingencies
- Lock-Up Agreements: The Company, executive officers, and directors agreed to a lock-up period ending on the later of:
- 45 days from the placement agent agreement date.
- The date of a public announcement regarding the outcome of a meeting with the FDA to discuss a potential New Drug Application (NDA) submission under the accelerated approval pathway.
- Registration Rights: The Company agreed to use commercially reasonable efforts to register the resale of restricted securities within 45 days and cause the registration statement to become effective within 90 days of the closing.
- Issuance Restrictions: Subject to exceptions, the Company cannot issue common stock or equivalents for 60 days (registration statements) or 6 months (Variable Rate Transactions) following the closing.
- Risk Factors: The filing notes that the offering is subject to customary closing conditions and that the Placement Agent is not required to sell a specific amount of securities.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received versus the expected $7.3 million total ($3.5M + $3.8M).
- Confirm the filing and effectiveness of the registration statement for the resale of restricted shares and warrants within the 45/90-day windows.
- Monitor the status of the FDA meeting regarding the accelerated approval pathway for CNM-Au8, as this dictates the end of the lock-up period.
- Review the specific terms of the Restricted Warrants (exercise price $4.82) to assess potential dilution impact relative to the current market price.
- Check for any subsequent filings regarding the use of proceeds or changes in the clinical trial timeline for CNM-Au8.